Allergy Drops Boxed Warning: What It Actually Applies To

Compounded liquid allergy drops do not carry an FDA boxed warning because they are used off-label and are not FDA-approved products. The boxed warning that people encounter applies to the FDA-approved sublingual immunotherapy tablets, which are a different category of treatment. Those tablets, such as Odactra, Grastek, Oralair, and Ragwitek, are single-allergen prescription drugs that went through the FDA approval process and carry the warning about severe allergic reactions. Liquid drops are custom-compounded for an individual's specific allergens and are not the same product. The absence of a boxed warning on liquid drops reflects their regulatory status, not a claim that they are risk-free; providers still take sensible safety precautions.

The boxed warning on FDA-approved sublingual immunotherapy tablets warns about the risk of severe, life-threatening allergic reactions, including anaphylaxis and laryngopharyngeal edema, which is swelling of the throat and voice box that can interfere with breathing. Because of this risk, the labeling instructs that the first dose be administered under the supervision of a healthcare professional and that patients be prescribed an epinephrine auto-injector. The warning also advises against starting the tablets in people with severe, unstable, or uncontrolled asthma. These precautions reflect the standard of care for any allergen immunotherapy. The warning is specific to the tablet products and is not an FDA label that exists for compounded liquid drops.

Neither product can be called safer in absolute terms, and a boxed warning is not a ranking of danger. A boxed warning means a product went through FDA approval and the agency required a prominent safety statement on its label. Compounded liquid drops do not have an FDA label at all because they are off-label, so the absence of a boxed warning is not evidence of greater safety. The available research shows sublingual immunotherapy in general, including both tablets and drops, has a favorable safety profile dominated by mild local reactions, with serious systemic reactions being rare. The right choice depends on your specific allergens and medical history, which is a discussion to have with your provider.

The allergen extracts used to make liquid drops are themselves FDA-approved for use in allergy diagnosis and subcutaneous immunotherapy, but the FDA has not approved the sublingual route for compounded multi-allergen liquid drops. Approval requires a manufacturer to run the formal clinical trials and submit an application for a specific product, which happened for the single-allergen tablets but not for custom liquid drop mixes. As a result, providers prescribe liquid drops off-label, a legal and common practice in medicine where an approved ingredient is used in a way not specifically approved. This is why liquid drops are generally not covered by insurance and do not carry FDA labeling such as a boxed warning.

There are four FDA-approved sublingual immunotherapy tablets in the United States, each targeting a single category of allergen. Grastek treats timothy grass pollen allergy and Oralair treats a mix of five grass pollens; both were approved in 2014. Ragwitek, also approved in 2014, treats ragweed pollen allergy. Odactra, approved in 2017, treats house dust mite allergy. Each is a once-daily tablet that dissolves under the tongue and carries the boxed warning about severe allergic reactions, along with instructions for a supervised first dose. These differ from compounded liquid drops, which are custom-mixed for an individual's specific combination of allergens and are used off-label rather than as FDA-approved products.